Autoantibodies to glutamic acid decarboxylase (GAD) in focal and generalized epilepsy: A study on 233 patients

Luca Errichiello, Giuseppe Perruolo, Angelo Pascarella, Pietro Formisano, Carlo Minetti, Salvatore Striano, Federico Zara, Pasquale Striano

Research output: Contribution to journalArticlepeer-review


Background: Autoantibodies to glutamic acid decarboxylase (GADA) have been associated to a wide range of neurologic conditions, including epilepsy. However, the spectrum of epileptic conditions associated with GADA is not completely established. We aimed to determine the occurrence of GADA in a large series of patients with different epilepsy types. Moreover, we assessed whether specific subgroups of patients are associated to GAD autoimmunity. Methods: GADA were measured by radioimmunoassay in a series of consecutive unselected epileptic patients observed over a 2-years-period. Patients with neuromuscular features, acute or subacute encephalopathic course, cognitive deterioration or psychiatric symptoms were excluded. Results: Two hundred thirty-three patients (121 women, mean age: 29.3 years; range: 6-78) were recruited. There were eighty-three (35.6%) patients with idiopathic (66 generalized, 17 focal) epilepsy; fifty-nine (25.3%) with cryptogenic (52 focal, 7 generalized) epilepsy, and ninety-one (39.0%) with symptomatic (75 focal, 16 generalized) epilepsy. GADA were detected in six (2.58%) patients. Two had idiopathic generalized epilepsy associated with diabetes mellitus type 1 (DM1); the other four patients suffered from cryptogenic temporal epilepsy and no history or signs of DM1. GADA positive patients could not be distinguished by seizure frequency or number of AEDs. However, in these cases, the mean epilepsy duration (8.5 ± 5.0 years) was shorter compared to the other 48 GADA-negative patients with cryptogenic focal epilepsy (17.3 ± 9.6) (p <0.0001). Conclusions: We confirm that GAD autoimmunity may be associated with some forms of epilepsy. The preferential identification in patients with cryptogenic temporal epilepsy deserves particularly further investigation.

Original languageEnglish
Pages (from-to)120-123
Number of pages4
JournalJournal of Neuroimmunology
Issue number1-2
Publication statusPublished - Jun 25 2009


  • Autoimmunity
  • Diabetes
  • Epilepsy
  • Glutamic acid decarboxylase antibodies

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Clinical Neurology
  • Neurology


Dive into the research topics of 'Autoantibodies to glutamic acid decarboxylase (GAD) in focal and generalized epilepsy: A study on 233 patients'. Together they form a unique fingerprint.

Cite this